Calidi Biotherapeutics, Inc.
CLDI
$1.36
$0.010.74%
AMEX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 7.99M | 9.47M | 10.50M | 10.61M | 10.99M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.85M | 19.37M | 20.24M | 19.80M | 19.98M |
| Operating Income | -17.85M | -19.37M | -20.24M | -19.80M | -19.98M |
| Income Before Tax | -17.49M | -19.09M | -20.05M | -20.13M | -20.03M |
| Income Tax Expenses | 17.00K | 16.00K | 15.00K | 20.00K | 9.00K |
| Earnings from Continuing Operations | -17.51 | -19.11 | -20.06 | -20.15 | -20.04 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 35.00K | 81.00K | 157.00K | 205.00K | 188.00K |
| Net Income | -17.47M | -19.03M | -19.91M | -19.95M | -19.85M |
| EBIT | -17.85M | -19.37M | -20.24M | -19.80M | -19.98M |
| EBITDA | -15.55M | -17.10M | -18.01M | -17.60M | -17.78M |
| EPS Basic | -54.19 | -83.00 | -111.49 | -153.88 | -242.61 |
| Normalized Basic EPS | -22.29 | -40.19 | -58.08 | -83.96 | -150.92 |
| EPS Diluted | -54.19 | -83.00 | -111.49 | -153.88 | -242.61 |
| Normalized Diluted EPS | -22.29 | -40.19 | -58.08 | -83.96 | -150.92 |
| Average Basic Shares Outstanding | 2.81M | 1.58M | 1.07M | 707.40K | 441.50K |
| Average Diluted Shares Outstanding | 2.81M | 1.58M | 1.07M | 707.40K | 441.50K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |